Lupimeg 500mg Tablet contains Imeglimin, a novel oral antihyperglycemic agent indicated for the treatment of type 2 diabetes mellitus. Imeglimin acts by targeting mitochondrial bioenergetics, improving insulin sensitivity, enhancing pancreatic beta-cell function, and reducing hepatic glucose production. This multifaceted mechanism helps in achieving better glycemic control in patients with type 2 diabetes. Lupimeg is typically prescribed as monotherapy or as an adjunct to other antidiabetic agents when diet and exercise alone do not provide adequate glycemic control. The recommended dosage is 500mg taken orally, with or without food, as directed by a healthcare professional. Clinical studies have demonstrated that Imeglimin effectively lowers HbA1c levels and fasting plasma glucose with a favorable safety profile. Common adverse effects are generally mild and may include gastrointestinal disturbances such as nausea or diarrhea. Lupimeg should be used cautiously in patients with renal impairment, and dose adjustments may be necessary. It is contraindicated in patients with known hypersensitivity to Imeglimin or any of the tablet excipients. Regular monitoring of blood glucose levels and renal function is advised during therapy to optimize treatment outcomes and minimize potential risks.